- Home
- RITR vs AMRN Comparison
RITR vs AMRN Comparison
Compare RITR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- AMRN
- Stock Information
- Founded
- RITR 2015
- AMRN 1989
- Country
- RITR Hong Kong
- AMRN Ireland
- Employees
- RITR N/A
- AMRN N/A
- Industry
- RITR
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- RITR
- AMRN Health Care
- Exchange
- RITR NYSE
- AMRN Nasdaq
- Market Cap
- RITR 227.3M
- AMRN 216.0M
- IPO Year
- RITR 2024
- AMRN 1993
- Fundamental
- Price
- RITR $3.36
- AMRN $11.59
- Analyst Decision
- RITR
- AMRN Sell
- Analyst Count
- RITR 0
- AMRN 2
- Target Price
- RITR N/A
- AMRN $7.00
- AVG Volume (30 Days)
- RITR 778.8K
- AMRN 76.9K
- Earning Date
- RITR 02-15-2025
- AMRN 05-07-2025
- Dividend Yield
- RITR N/A
- AMRN N/A
- EPS Growth
- RITR N/A
- AMRN N/A
- EPS
- RITR 0.09
- AMRN N/A
- Revenue
- RITR $47,948,887.00
- AMRN $214,112,000.00
- Revenue This Year
- RITR N/A
- AMRN N/A
- Revenue Next Year
- RITR N/A
- AMRN $5.97
- P/E Ratio
- RITR $39.01
- AMRN N/A
- Revenue Growth
- RITR 278.44
- AMRN N/A
- 52 Week Low
- RITR $2.24
- AMRN $7.08
- 52 Week High
- RITR $8.75
- AMRN $17.58
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- AMRN 65.14
- Support Level
- RITR N/A
- AMRN $10.85
- Resistance Level
- RITR N/A
- AMRN $11.84
- Average True Range (ATR)
- RITR 0.00
- AMRN 0.49
- MACD
- RITR 0.00
- AMRN 0.06
- Stochastic Oscillator
- RITR 0.00
- AMRN 86.56
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.